Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae297 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Oncologist, 2025. Verfasst von Karam Khaddour und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins c-raf, Protein Kinase Inhibitors, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ladieu Family Melanoma Research Fund.
Abstract (Originalsprache)
The biological and clinical relevance of gene fusions in melanoma is unknown. Reports and preclinical data have suggested that tumor cells with specific rearrangements such as RAF1 gene fusions could be therapeutically targeted. To investigate the relevance of targeted therapy in patients with melanoma harboring RAF1 gene fusions, we reviewed records of 1268 melanoma patients with targeted sequencing data at the Dana-Farber Cancer Institute. We identified 9 cases and report here on their clinicopathologic characteristics. We describe the favorable outcome of 2 patients who received MEK inhibitor therapy, including 1 patient with a durable response. We coalesced our data with published reports of patients with RAF1 gene fusions who were treated with targeted therapy. We find that single-agent MEK inhibition has anti-tumor activity in melanoma patients harboring an RAF1 gene fusion, and we propose that patients with RAF1 gene fusions should be considered for single-agent MEK inhibitor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.
- Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, MA 02115, United States.
- Harvard Medical School, Boston, MA 02115, United States.
ORCID-Profile: Karam Khaddour, Megan L Insco
Förderung
- Ladieu Family Melanoma Research Fund
Zitieren
APA
Khaddour, K., Haq, R., Buchbinder, E. I., Liu, D., Manos, M. P., Ott, P. A., Hodi, F. S., & Insco, M. L. (2025). Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae297
Vancouver
Khaddour K, Haq R, Buchbinder EI, Liu D, Manos MP, Ott PA, et al. Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma. The Oncologist. 2025. doi:10.1093/oncolo/oyae297
BibTeX
@article{Khaddour2025,
author = {Khaddour, Karam and Haq, Rizwan and Buchbinder, Elizabeth I and Liu, David and Manos, Michael P and Ott, Patrick A and Hodi, F Stephen and Insco, Megan L},
title = {Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae297}
}
EUVIMED